/pdf/secretory-products-of-macrophages-5cf7rlxshh.pdf

Secretory products of macrophages.

The biology of interleukin-6.

The alphaviruses: gene expression, replication, and evolution.

Lymphocyte responses and cytokines

Evidence-based guidelines for the management of patients with Lyme disease, human granulocytic anaplasmosis (formerly known as human granulocytic ehrlichiosis), and babesiosis were prepared by an expert panel of the Infectious Diseases Society of America. These updated guidelines replace the previous treatment guidelines published in 2000 (Clin Infect Dis 2000; 31[Suppl 1]:1-14). The guidelines are intended for use by health care providers who care for patients who either have these infections or may be at risk for them. For each of these Ixodes tickborne infections, information is provided about prevention, epidemiology, clinical manifestations, diagnosis, and treatment. Tables list the doses and durations of antimicrobial therapy recommended for treatment and prevention of Lyme disease and provide a partial list of therapies to be avoided. A definition of post-Lyme disease syndrome is proposed.

/pdf/the-clinical-assessment-treatment-and-prevention-of-lyme-xajvcef2ye.pdf

The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America

Pillars Article: Identification of a T Cell-Derived B Cell Growth Factor Distinct from Interleukin 2. J. Exp. Med. 1982. 155: 914–923

Significant improvement of the recombinant Borrelia IgG immunoblot for serodiagnosis of early neuroborreliosis

The present invention relates to isolated Chaperonin 10 polypeptides possessing immunomodulatory activity, but lacking, or substantially lacking, protein folding activity.

Modified chaperonin 10

Compositions and methods of the present invention relating to B. burgdorferi HtrA sensu lato (BbHtrA) protease activity, its substrates, cleavage products, biological effects and use in detection, diagnosis and/or treatment of Lyme disease are provided.

Compositions and methods relating to lyme disease

Background: Chaperonin 10 (Cpn10) is a mitochondrial protein essential for protein folding In vitro studies have also shown that Cpn10 reduces production of pro-inflammatory cytokines and chemokines, and up-regulates interleukin-10 in response to agonist stimulation of Toll-like receptors A protective effect for Cpn10 in experimental autoimmune encephalomyelitis has been demonstrated with suppression of inflammatory markers Here we report the first clinical trials of this agent administered intravenously in human subjects Methods: Two dose ranging and tolerability studies were undertaken in 16 healthy volunteers (Phase Ia - single doses of 1 mg, 25 mg, 5 mg or 10 mg with 1:3 subjects receiving placebo) and 10 patients with multiple sclerosis (Phase Ib - 5 daily doses of 25 mg or 5 mg with 1:4 patients receiving placebo) using a double-blind, randomised design Intravenous administration was over 10 minutes Adverse events, clinical data, pharmacodynamic and pharmacological parameters were monitored Results: There were no serious adverse events and no discernible trends observed for other adverse events The half-life of Cpn10 was approximately one hour and suppression of TNF-a production in a peripheral blood mononuclear cell assay was seen when blood was taken 8-hr post dose A peak dose pharmacodynamic effect was seen at 5 mg No significant increase in anti-Cpn10 antibodies was seen There was no discernable clinical effect in the multiple sclerosis volunteers Conclusions: Cpn10 is well tolerated when administered intravenously to both healthy and multiple sclerosis affected human subjects Anticipated modulation of the innate immune system was observed in both healthy and affected subjects

Barbara J. B. Johnson

Papers

Pillars Article: Identification of a T Cell-Derived B Cell Growth Factor Distinct from Interleukin 2. J. Exp. Med. 1982. 155: 914–923

Significant improvement of the recombinant Borrelia IgG immunoblot for serodiagnosis of early neuroborreliosis

Modified chaperonin 10

Compositions and methods relating to lyme disease

Phase Ia and Ib clinical Trials of chaperonin 10 in healthy volunteers and patients with multiple sclerosis